Symbiomix Therapeutics, a Newark, N.J.-based late-stage, privately held biopharmaceutical company, closed the third and final tranche of a $41m Series A financing.
Investors included OrbiMed, Fidelity BioSciences, and HBM Partners, as well as financial services partner Square 1 Bank.
The company intends to use the funds to advance SYM-1219 through Phase 3 and towards the filing of an NDA.
Founded in 2012, Symbiomix is developing innovative medicines for serious women’s health infections. The company’s lead drug candidate is SYM-1219, a novel product containing secnidazole, which is a next-generation 5-nitroimidazole antibiotic. It has just completed a multi-center, randomized Phase 2 trial testing a single oral dose of SYM-1219 for the treatment of bacterial vaginosis (BV). Based on discussions with the U.S. Food and Drug Administration (FDA) at an End-of-Phase 2 meeting, the Company now is planning to submit the Phase 2 trial as one of two pivotal studies for a New Drug Application (NDA) filing in 2016. Simultaneously, the company announced that the FDA recently designated SYM-1219 as a Qualified Infectious Disease Product (QIDP).
Led by Klaus Veitinger, M.D., Ph.D., CEO, Joseph L. Amprey, M.D., Ph.D., Chief Business Officer, Robert Jacks, President & CFO, and Carol J. Braun, M.D., Chief Medical Officer, Symbiomix also has offices in Maryland and Connecticut.